PA-PHLEXGLOBAL
Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry announces the release of the Completeness Quality Control (CQC) module as part of PhlexEview®, its market leading eTMF solution.
Phlexglobal has taken its exclusive, in-house best practice TMF quality technology and made it available as a unique product module of PhlexEview. Building on existing PhlexEview functionality, the CQC module takes TMF management and oversight to another level replacing manual processes with robust in-line technology to facilitate planning, execution, oversight, closure and archive of the TMF. The CQC module provides the tools to conduct regular, risk based or milestone driven completeness reviews within the eTMF system, enabling an up-to-date picture of the quality, completeness and timeliness of a TMF to support inspection readiness.
Firmly integrated with PhlexEview’s powerful workflow capabilities, the flexibility of the CQC module allows statistical sampling for reviews and automated cross checks between related documents, associating them to trial milestones and events. The Investigational Product (IP) release to site process can now be fully managed within PhlexEview; using the CQC module to package, review and approve documents.
Oversight is enabled by the CQC module’s unique TMF Heatmap technology, allowing visualization of real-time metrics on the quality, completeness and timeliness of your TMF down to zone, section, artifact, owner and submitter. In addition, built in reporting tools allow for deep insight into CQC data for trend analysis, issue specifics and remediation management.
The CQC module is also integrated with PhlexEview’s eQuery capability so queries are automatically categorized and tracked, supporting comprehensive reporting and management of findings through to remediation. Working with PhlexEview’s placeholder feature, any missing document findings can automatically create placeholders through events. This flexibility allows clients to configure the CQC module to meet both client and trial specific requirements, supporting TMF inspection readiness.
CEO Rick Riegel said “Phlexglobal has applied its unrivalled experience and expertise to create this innovative CQC module. Over a million TMF documents have already been through our CQC service, for ongoing, milestone, pre-inspection and end of study CQC, with more than 160 trials reviewed.”
The CQC module will be showcased in a webinar featuring a live demonstration of the module as part of the latest version of PhlexEview 4, on Tuesday 25th April 2017 at 3pm BST/ 4pm CET/10am EST. To register for the webinar please visit our website at: http://www.phlexglobal.com/webinar-phlexeviewqc/
About Phlexglobal
Phlexglobal is a specialist provider of both industry leading eTMF technology solutions and expert TMF & eTMF technology-enabled services. Offering a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise, we deliver a range of flexible, targeted solutions to meet business needs.
More information can be found at: http://www.phlexglobal.com
-Ends-
View source version on businesswire.com: http://www.businesswire.com/news/home/20170331005207/en/
Contact:
Phlexglobal Ltd
Gillian Gittens, head of marketing
Tel:
+44(0)1494 720420
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 02:45:00 CEST | Press release
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in Adults and Children with VWD1 − VWD, the Most Common Bleeding Disorder, Impacts More Than 3 Million People in the U.S.2 Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approve
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20255.9.2025 23:34:00 CEST | Press release
From well-being to energy efficiency, Bespoke AI, Vision AI, and Galaxy AI transform the way we live and connect. At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology support
Andersen Consulting styrker end-to-end-teknologikompetencer via samarbejde med FirstQA Systems5.9.2025 19:44:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation og kunstig intelligens via en samarbejdsaftale med FirstQA Systems, der er en førende teknologileverandør, som er kendt for sin ekspertise inden for AI til virksomheder, digital transformation og cybersikkerhed. FirstQA Systems K.K. med hovedsæde i Japan siden 2011 er en konsulentdrevet teknologivirksomhed, der betjener Fortune 500-virksomheder og multinationale koncerner i Asien, Europa og Nordamerika. Virksomheden specialiserer sig i kunstig intelligens, digital transformation (med fokus på platformene ServiceNow, SAP og Salesforce) samt it- og OT-cybersikkerhed. Gennem sit datterselskab, Himitsu Lab Limited, leverer FirstQA Systems banebrydende Agentic AI-løsninger drevet af HIMITSU8™ Unified Development Framework (UDF)™. Virksomhedens brancheekspertise dækker bl.a. produktion, medicinalindustrien samt løsninger til bank- og finansverdenen. "Vores samarbejde med Andersen Consulting markerer et spændende sk
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 17:15:00 CEST | Press release
Recognition reflects NetApp’s Ability to Execute and Completeness of Vision NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.”
Motive’s Entitlement Server Acknowledged as a Pacesetter in Counterpoint Research’s 2025 Rankings5.9.2025 15:00:00 CEST | Press release
Motive, a global leader in device management, today announced its recognition as a Pacesetter in Counterpoint Research’s 2025 Entitlement Server Rankings. Counterpoint placed Motive in its highest top-right Pacesetter quadrant: the most advanced recognition in the ranking. This accolade reflects Motive’s decisive investment in entitlement orchestration at a time when operators face urgent deadlines, including Apple’s September 2025 RCS requirement. Motive has taken the lead, proving ability to deliver at scale, currently deployed in large mobile service providers across North America, Europe, Africa, the Middle East, Asia-Pacific, and Latin America. Removing Barriers to RCS and Beyond The industry has long wrestled with the lack of a commercial framework for Rich Business Messaging (RBM) and lack of cross platform support between Android and iOS. Motive addresses this by ensuring operators can enable RCS on both Apple and Android devices securely without delay. This approach derisks op
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom